BACKGROUND: Prior to the 2008 advent of sorafenib, traditional cytotoxic agents were the therapeutic mainstay for patients with advanced hepatocellular carcinoma (HCC). We thus undertook a clinical study of sorafinib and conventional cytotoxic therapy for HCC, comparing efficacy and safety. METHODS: From January, 2002 to December, 2009, 173 patients with unresectable HCC were reviewed retrospectively. Among them, 44 (25.4%) had been treated with sorafenib, and the remainder had received cytotoxic therapy (CTX). We evaluated objective response rate (ORR), progression free survival (PFS), overall survival (OS), and toxicity profiles. RESULTS: Median OS of sorafinib was 23.0 weeks (95% CI, 8.1-37.9) vs 43.6 weeks (95% CI, 34.0-53.2) for CTX....
Abstract Background Before the targeted therapies era, cytotoxic chemotherapy (CCT) was an option fo...
Introduction: Sorafenib was the first therapy used for systemic treatment of unresectable hepatocell...
Phase III trials show sorafenib improves survival in advanced hepatocellular carcinoma (HCC). Becaus...
Background: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and has high mo...
BACKGROUND: No effective systemic therapy exists for patients with advanced hepatocellular carcinoma...
Objectives: Hepatocellular carcinoma (HCC) is a heterogeneous disease. We explored whether any speci...
PURPOSE: Advanced hepatocellular carcinoma (HCC) not eligible for local therapies has limited chance...
Yizhuo Wang,1,2 Qing Gou,1 Rongde Xu,1 Xiaoming Chen,1 Zejian Zhou1 1Department of Interventional O...
Chi-Chun Huang,1 Hsin-Yi Chen,1 Ruei-Hsin Chang,1 Pen-An Liao,2 Heng-Hui Lien,3,4 Chih-Sheng Hung,5 ...
Background & AimsThe Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP)...
Hui Wang, Hefang Wang, Zhichong Yu, Honghao Liu Department of Radiation Oncology, Yancheng First Pe...
Background: Although sorafenib is accepted as the standard of care in advanced hepatocellular carcin...
The efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) remains contro...
BACKGROUND & AIMS: The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHAR...
Purpose:Severe adverse events frequently occur in patients treated with sorafenib, whereas some pati...
Abstract Background Before the targeted therapies era, cytotoxic chemotherapy (CCT) was an option fo...
Introduction: Sorafenib was the first therapy used for systemic treatment of unresectable hepatocell...
Phase III trials show sorafenib improves survival in advanced hepatocellular carcinoma (HCC). Becaus...
Background: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and has high mo...
BACKGROUND: No effective systemic therapy exists for patients with advanced hepatocellular carcinoma...
Objectives: Hepatocellular carcinoma (HCC) is a heterogeneous disease. We explored whether any speci...
PURPOSE: Advanced hepatocellular carcinoma (HCC) not eligible for local therapies has limited chance...
Yizhuo Wang,1,2 Qing Gou,1 Rongde Xu,1 Xiaoming Chen,1 Zejian Zhou1 1Department of Interventional O...
Chi-Chun Huang,1 Hsin-Yi Chen,1 Ruei-Hsin Chang,1 Pen-An Liao,2 Heng-Hui Lien,3,4 Chih-Sheng Hung,5 ...
Background & AimsThe Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP)...
Hui Wang, Hefang Wang, Zhichong Yu, Honghao Liu Department of Radiation Oncology, Yancheng First Pe...
Background: Although sorafenib is accepted as the standard of care in advanced hepatocellular carcin...
The efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) remains contro...
BACKGROUND & AIMS: The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHAR...
Purpose:Severe adverse events frequently occur in patients treated with sorafenib, whereas some pati...
Abstract Background Before the targeted therapies era, cytotoxic chemotherapy (CCT) was an option fo...
Introduction: Sorafenib was the first therapy used for systemic treatment of unresectable hepatocell...
Phase III trials show sorafenib improves survival in advanced hepatocellular carcinoma (HCC). Becaus...